Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

NCT ID: NCT01319812

Last Updated: 2019-03-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 463 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-07-31
• Study Completion Date: 2017-09-07

Brief Summary

The objective of this study is to separately demonstrate the safety and efficacy of BIOTRONIK's Astron and Pulsar stents. The Pulsar stent will be used for the treatment of femoro-popliteal lesions, located in the native superficial femoral artery (SFA) or proximal popliteal artery (PPA), while the Astron stent will be used for the treatment of the common or external iliac artery lesions.

Conditions

Peripheral Artery Disease; Peripheral Vascular Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Astron Stent Group

Participants indicated for stenting in iliac atherosclerotic lesions.

Intervention: Device: Astron Stents

Group Type: EXPERIMENTAL

Astron Stents

Intervention Type: DEVICE

Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.

Pulsar Stent Group

Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.

Intervention: Device: Pulsar Stents

Group Type: EXPERIMENTAL

Pulsar Stents

Intervention Type: DEVICE

Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.

Interventions

Astron Stents

Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.

Intervention Type: DEVICE

Pulsar Stents

Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.

Intervention Type: DEVICE

Other Intervention Names

Astron Stent; Astron Pulsar Stent; Pulsar-18 Stent; Pulsar Stent

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Willingness to comply with study follow-up requirements
• Candidate for PTA
• Life-style limiting claudication or rest pain with an ABI ≤ 0.9 (resting or exercise). Thigh brachial index (TBI) may be used / performed if ABI is inadequate.
• Written informed consent

For a subject to receive an investigational stent, the following procedure-related criteria must be met:

• One de novo, restenotic or occluded lesion representing a femoro-popliteal or iliac indication OR Two de novo, restenotic or occluded lesions representing one femoro-popliteal indication and one iliac indication on contralateral limbs - (i.e. one lesion per limb)
• Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated as one lesion
• Subjects with bilateral, SFA/PPA disease (i.e. one SFA/PPA lesion per limb) are eligible for enrollment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral SFA/PPA intervention may be performed at the time of the index procedure (prior to treatment of study lesion); however, the use of an investigational treatment is prohibited. If the contralateral SFA/PPA intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the contralateral intervention is prohibited.
• Subjects with bilateral, iliac disease (i.e. one iliac lesion per limb) are eligible for enrollment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral iliac intervention may be performed at the time of the index procedure; however, the use of an investigational treatment is prohibited. If the contralateral iliac intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the subsequent contralateral intervention is also prohibited.
• Femoro-popliteal lesions must be located at least 1 cm distal to the profunda femoris artery and at least 3 cm above the knee joint (radiographic joint space)
• Iliac lesions must be located only in either the common or external iliac artery
• Lesions must be treatable with a maximum of two stents
• Angiographic evidence of ≥ 70% stenosis or occlusion (operator visual assessment)
• Lesion length ≤ 190 mm (if de novo or restenotic) or ≤ 100 mm (if occluded)
• Target vessel reference diameter: 2.5 to 6 mm (SFA/PPA) or 6 to 9 mm (iliac arteries) by visual estimate
• Angiographic evidence of patent SFA and PPA (iliac indication) and angiographic evidence of at least one distal vessel runoff to the foot (both femoro-popliteal and iliac indications). Patent is defined as < 50% stenosis.
• For SFA/PPA intervention, a significant stenosis (> 70%) or occlusion of an ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully treated (use of investigational treatment prohibited) just prior to treatment of the target lesion. Successful treatment is defined as no complications and less than 30% residual stenosis following intervention.

Exclusion Criteria

• Subjects pregnant or planning to become pregnant during the course of the study
• Life expectancy of less than one year
• Rutherford-Becker category 5 or 6. Subjects with ulcers caused by venous disease may be enrolled in the study.
• Previously stented lesion(s) in the target vessel
• Target lesion(s) received previous treatment within 30 days prior to enrollment
• Prior peripheral vascular bypass surgery involving the target limb(s)
• Thrombophlebitis or deep vein thrombosis within the past 30 days
• Known allergy to nitinol (nickel and/or titanium)
• Participation in any other clinical investigational device or drug study. Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the investigational treatment or protocol of this study.
• Previous stroke or transient ischemic attack within the last three months prior to enrollment
• Previous coronary or peripheral bypass surgery (non-target limb) within 30 days prior to enrollment
• Intolerance to contrast agents that cannot be medically managed and/or intolerance to anti-platelet, anti-coagulant or thrombolytic medications
• Refuses blood transfusions
• Any medical condition, that in the opinion of the investigator, poses an unacceptable risk for implant of a stent according to the study indications

For a subject to receive an investigational stent the following procedure-related criteria must not be present:

• INR ≥ 1.6
• Concomitant renal failure with serum creatinine level > 2.5 mg/dL
• Unresolved neutropenia (white blood cell count < 3,000 / µL) or thrombocytopenia (platelet count < 80,000 / µL) at the time of the index procedure
• Unresolved bleeding disorder (INR ≥ 1.6) at the time of the index procedure
• Presence of other ipsilateral, arterial lesions distal to the target lesion requiring treatment within 30 days of the index procedure (either before or after) or at the time of the index procedure
• Additional percutaneous interventional procedures (cardiac and/or peripheral) planned within 30 days after the index procedure
• Presence of a complication following pre-dilation of target lesion
• Presence of a target vessel/lesion that is excessively tortuous or calcified or is adjacent to an acute thrombus that is unresponsive to anti-thrombotic therapies
• Target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion
• Target lesion requires the use of cutting balloons, atherectomy or ablative devices
• Subjects with less than single vessel runoff to the foot

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biotronik, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Burket, MD

Role: PRINCIPAL_INVESTIGATOR

University of Toledo

Locations

Fremont, California, United States

New Haven, Connecticut, United States

Washington D.C., District of Columbia, United States

Rockford, Illinois, United States

Munster, Indiana, United States

Houma, Louisiana, United States

Lansing, Michigan, United States

Saginaw, Michigan, United States

Wyoming, Michigan, United States

Ypsilanti, Michigan, United States

Tupelo, Mississippi, United States

Kansas City, Missouri, United States

Ridgewood, New Jersey, United States

New York, New York, United States

The Bronx, New York, United States

Gastonia, North Carolina, United States

High Point, North Carolina, United States

Cincinnati, Ohio, United States

Toledo, Ohio, United States

Toledo, Ohio, United States

Camp Hill, Pennsylvania, United States

Doylestown, Pennsylvania, United States

Langhorne, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Providence, Rhode Island, United States

Greenville, South Carolina, United States

Rock Hill, South Carolina, United States

Kingsport, Tennessee, United States

Amarillo, Texas, United States

Austin, Texas, United States

McKinney, Texas, United States

Tyler, Texas, United States

Waco, Texas, United States

Montreal, , Canada

Toronto, , Canada

Countries

United States; Canada

References

Burket MW, Brodmann M, Metzger C, Tan K, Jaff MR. Twelve-Month Results of the Nitinol Astron Stent in Iliac Artery Lesions. J Vasc Interv Radiol. 2016 Nov;27(11):1650-1656.e1. doi: 10.1016/j.jvir.2016.06.008. Epub 2016 Aug 16.

Reference Type: BACKGROUND

PMID: 27542591 (View on PubMed)

Other Identifiers

BIOFLEX-I

Identifier Type: -

Identifier Source: org_study_id